Cargando…

MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer

Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: de Miguel-Luken, María-José, Chaves-Conde, Manuel, de Miguel-Luken, Verónica, Muñoz-Galván, Sandra, López-Guerra, José Luis, Mateos, Juan C., Pachón, Jerónimo, Chinchón, David, Suarez, Vladimir, Carnero, Amancio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494962/
https://www.ncbi.nlm.nih.gov/pubmed/25788275
_version_ 1782380179106037760
author de Miguel-Luken, María-José
Chaves-Conde, Manuel
de Miguel-Luken, Verónica
Muñoz-Galván, Sandra
López-Guerra, José Luis
Mateos, Juan C.
Pachón, Jerónimo
Chinchón, David
Suarez, Vladimir
Carnero, Amancio
author_facet de Miguel-Luken, María-José
Chaves-Conde, Manuel
de Miguel-Luken, Verónica
Muñoz-Galván, Sandra
López-Guerra, José Luis
Mateos, Juan C.
Pachón, Jerónimo
Chinchón, David
Suarez, Vladimir
Carnero, Amancio
author_sort de Miguel-Luken, María-José
collection PubMed
description Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence available to establish the group of patients that may benefit from preservation approaches and clinical criteria such as primary tumor extension or pretreatment tracheotomy are not validated. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The tumoral behavior induced by MAP17 is associated with reactive oxygen species production in which SGLT1 seems involved. In this study we found that the levels of MAP17 were related to clinical findings and survival in a cohort of 58 patients with larynx cancer. MAP17 expression is associated with overall survival (p<0.001) and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control in patients with high MAP17 showed better outcomes than those with low MAP17 (p=0.016). Besides, a positive correlation was observed between MAP17 expression and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to an increased overall survival (p=0,028). These findings suggest that MAP17, alone or in combination with SGLT1, may become a novel predictive biomarker for laryngeal carcinoma.
format Online
Article
Text
id pubmed-4494962
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44949622015-07-13 MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer de Miguel-Luken, María-José Chaves-Conde, Manuel de Miguel-Luken, Verónica Muñoz-Galván, Sandra López-Guerra, José Luis Mateos, Juan C. Pachón, Jerónimo Chinchón, David Suarez, Vladimir Carnero, Amancio Oncotarget Research Paper Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence available to establish the group of patients that may benefit from preservation approaches and clinical criteria such as primary tumor extension or pretreatment tracheotomy are not validated. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The tumoral behavior induced by MAP17 is associated with reactive oxygen species production in which SGLT1 seems involved. In this study we found that the levels of MAP17 were related to clinical findings and survival in a cohort of 58 patients with larynx cancer. MAP17 expression is associated with overall survival (p<0.001) and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control in patients with high MAP17 showed better outcomes than those with low MAP17 (p=0.016). Besides, a positive correlation was observed between MAP17 expression and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to an increased overall survival (p=0,028). These findings suggest that MAP17, alone or in combination with SGLT1, may become a novel predictive biomarker for laryngeal carcinoma. Impact Journals LLC 2015-02-28 /pmc/articles/PMC4494962/ /pubmed/25788275 Text en Copyright: © 2015 de Miguel-Luken et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
de Miguel-Luken, María-José
Chaves-Conde, Manuel
de Miguel-Luken, Verónica
Muñoz-Galván, Sandra
López-Guerra, José Luis
Mateos, Juan C.
Pachón, Jerónimo
Chinchón, David
Suarez, Vladimir
Carnero, Amancio
MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
title MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
title_full MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
title_fullStr MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
title_full_unstemmed MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
title_short MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
title_sort map17 (pdzkip1) as a novel prognostic biomarker for laryngeal cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494962/
https://www.ncbi.nlm.nih.gov/pubmed/25788275
work_keys_str_mv AT demiguellukenmariajose map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT chavescondemanuel map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT demiguellukenveronica map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT munozgalvansandra map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT lopezguerrajoseluis map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT mateosjuanc map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT pachonjeronimo map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT chinchondavid map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT suarezvladimir map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer
AT carneroamancio map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer